Additional Drug Resistance Patterns among Multidrug-Resistant Tuberculosis Patients in Korea: Implications for Regimen Design.
10.3346/jkms.2017.32.4.636
- Author:
Jeong Ha MOK
1
;
Bo Hyoung KANG
;
Taehoon LEE
;
Hyun Kyung LEE
;
Hang Jea JANG
;
Yu Ji CHO
;
Doosoo JEON
Author Information
1. Department of Internal Medicine, Pusan National University Hospital, Busan, Korea.
- Publication Type:Original Article
- Keywords:
Drug Resistance;
Tuberculosis;
Tuberculosis, Multidrug-Resistant;
Extensively Drug-Resistant Tuberculosis;
Korea
- From:Journal of Korean Medical Science
2017;32(4):636-641
- CountryRepublic of Korea
- Language:English
-
Abstract:
Detailed information on additional drug resistance patterns of multidrug-resistant tuberculosis (MDR-TB) is essential to build an effective treatment regimen; however, such data are scarce in Korea. We retrospectively analyzed the results of phenotypic drug susceptibility testing (DST) of culture confirmed-TB patients from January 2010 to December 2014 in 7 university hospitals in Korea. MDR-TB was identified among 6.8% (n = 378) of 5,599 isolates. A total of 57.1% (n = 216) of the MDR-TB patients had never been treated for TB. Strains from MDR-TB patients showed additional resistance to pyrazinamide (PZA) (35.7%), any second-line injectable drug (19.3%), and any fluoroquinolone (26.2%). Extensively drug resistant TB comprised 12.4% (n = 47) of the MDR-TB patients. Of 378 MDR-TB patients, 50.3% (n = 190) were eligible for the shorter MDR-TB regimen, and 50.0% (n = 189) were fully susceptible to the 5 drugs comprising the standard conventional regimen (PZA, kanamycin, ofloxoacin, prothionamide, and cycloserine). In conclusion, the proportion of new patients and the levels of additional drug resistance were high in MDR-TB patients. Considering the high levels of drug resistance, the shorter MDR-TB treatment regimen may not be feasible; instead, an individually tailored regimen based on the results of molecular and phenotypic DST may be more appropriate in MDR-TB patients in Korea.
